# Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma

> **NCT01181895** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 348 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Vilanterol
- **DRUG:** Salmeterol Inhalation Powder
- **DRUG:** Placebo Inhalation Powder NDPI
- **DRUG:** Placebo Inhalation Powder Diskus

## Key facts

- **NCT ID:** NCT01181895
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09-01
- **Primary completion:** 2011-08-01
- **Final completion:** 2011-08-26
- **Target enrollment:** 348 (ACTUAL)
- **Last updated:** 2017-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01181895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01181895, "Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01181895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*